On January 29th, MEDSIR hosted its inaugural brainstorming session for 2024, centering around thoracic malignancies. A distinguished panel of four international oncologists graced the occasion: Dr. Giuseppe Banna (Portsmouth Hospitals University NHS), Dr. Antonio Calles (Hospital General Universitario Gregorio Marañón), Dr. Alfredo Addeo (University Hospital of Geneva), and Dr. Carles Escriu (The Clatterbridge Cancer Centre NHS).
Left to right: Dr. Carles Escriu, Giulia Raimondi, Dr. Giuseppe Banna, Dr. Alfredo Addeo, Felipe Slebe, Federica Turrisi, Dr. Antonio Calles and Maria Angulo.
The primary objective of these Brainstorming Series is to delve into the latest cancer research, fostering the creation of innovative ideas that can be translated into strategic investigator-initiated clinical trials (IITs) addressing both current and future clinical needs.
This particular session delved deeply into thoracic malignancies, spotlighting two critical areas: early-stage Non-small cell lung cancer (NSCLC) and Small cell lung cancer (SCLC).
Guiding the session, Dr. Giuseppe Banna opened with a warm welcome from our Strategic Research Development Chief, Giulia Raimondi, PhD. Presentations by Dr. Giuseppe Banna and Dr. Antonio Calles followed, offering insights into their experiences with MEDSIR and ongoing projects, such as the LUPER trial.
The core of the session revolved around discussing unmet needs and relevant talking points within SCLC and early-stage NSCLC. Beginning with SCLC, a spirited conversation unfolded on the development of strategic IITs, yielding compelling ideas that directly addressed the previously identified unmet needs.
Following the exploration of promising designs, we paused for a communal lunch, providing an opportunity to build connections and engage in stimulating conversations, enhancing mutual understanding.
The afternoon session shifted focus to Non-small cell lung cancer, specifically its early stage. After an examination of unmet needs, we resumed brainstorming, generating ideas that were not only captivating but also in alignment with the identified gaps and necessities in the field. The session wrapped up with a recap of key points and strategizing for future steps and meetings.
At MEDSIR, our aim with the Brainstorming Series is to transform it into a recurring and distinctive event. This platform provides oncologists with the opportunity to engage in discussions while remaining tuned in to emerging needs and exploring possibilities for Investigator-Initiated Trials (IITs).
Our subsequent meeting is slated for the European Lung Cancer Congress 2024 in Prague from March 20-23, where we will reconvene to discuss proposals and updates.
In summary, the session was a triumph, marked by the emergence of fresh ideas and valuable networking with internationally acclaimed oncologists.
We eagerly anticipate translating their suggestions into impactful clinical trials.
Stay tuned for our next session on March 8th, concentrating on Genitourinary (GU) malignancies!
How about you? Would you like to join a brainstorming session? Feel free to reach out to us, and let's explore what we can achieve together.
Comments